ライフサイエンスコーパス: adenosine receptor

1 enylxanthine (DPSPX) (0.1 muM; antagonist of adenosine receptors).

2 ulfur phasing of the human G protein-coupled adenosine receptor.

3 inopyridine or a selective agonist of the A3 adenosine receptor.

4 ine/paracrine signaling molecule through A2b adenosine receptor.

5 n mice lacking the renal proximal tubular A1 adenosine receptor.

6 rotection by ENT inhibitors involves the A2B adenosine receptor.

7 s as potent allosteric enhancers of the A(1) adenosine receptor.

8 icating involvement of a Galpha(i/o)-coupled adenosine receptor.

9 leep behavior independently of the one known adenosine receptor.

10 cule found in adipose tissue depots, acts on adenosine receptors.

11 phosphate production by cells overexpressing adenosine receptors.

12 y hydrolyzed extracellular AMP and activated adenosine receptors.

13 f presynaptic adenosine signaling through A1 adenosine receptors.

14 back, namely by providing the ligand for A2A adenosine receptors.

15 tumor immune responses via activation of A2A adenosine receptors.

16 stimulating effects through the blockade of adenosine receptors.

17 neurotransmitter release acting through A(1) adenosine receptors.

18 mediated by astrocyte endocytic function and adenosine receptors.

19 tamate release via activation of presynaptic adenosine receptors.

20 ully an uncovered selectivity issue with the adenosine receptors.

21 e.g., extracellular loop (EL) 3 in the A(2A) adenosine receptor].

22 overexpress mRNA for dopamine receptor 2 and adenosine receptor 2a in the striatum, markers of medium

23 emia, including signaling events through the adenosine receptor 2b (Adora2b).

24 The adenosine receptor 2B antagonist MRS1754 inhibited mecha

25 levels, as well as upregulated expression of adenosine receptor 3 (ADORA3) and genes related to adeno

26 In addition, mice deficient in the adenosine receptor A(2A) were more susceptible to immuno

27 A((2)A) adenosine receptor (A((2)A)AR) has been shown to possess

28 selective and affine PET ligand for the A(1) adenosine receptor (A(1)AR).

29 We report the crystal structure of the A(2A) adenosine receptor (A(2A)AR) bound to an agonist UK-4320

30 trate that overexpression of the human A(2A) adenosine receptor (A(2A)AR) in vascular endothelial cel

31 These compounds were evaluated as A(2A) adenosine receptor (A(2A)R) agonists in a cAMP accumulat

32 The cAMP-elevating A(2b) adenosine receptor (A(2b)AR) controls inflammation via i

33 adenosine acts via dendritic cell (DC) A(2B) adenosine receptor (A(2B)AR) to promote the development

34 osine levels and the inhibition of the A(2B) adenosine receptor (A(2B)R) attenuated renal fibrosis an

35 We demonstrate A(3) adenosine receptor (A(3)AR) agonism as a new target-base

36 gh the activation of the A(1)-subtype of the adenosine receptors (A(1)AR) is arrhythmogenic in the de

37 Activating A(1) adenosine receptors (A(1)ARs) increased total MMP-2 and

38 A(1) adenosine receptors (A(1)Rs) are antagonized by caffeine

39 A(2B) adenosine receptors (A(2B)ARs) are the predominant adeno

40 Activation of A(3) adenosine receptors (A(3)ARs) rapidly enhances the activ

41 An antagonist of the A2A adenosine receptor, a G-protein-coupled receptor that is

42 ge, new cholesterol-binding sites on the A2A adenosine receptor, a G-protein-coupled receptor that is

43 MD/FEP) in fragment optimization for the A2A adenosine receptor, a pharmaceutically relevant G protei

44 levels of ATP metabolites and expression of adenosine receptor A1, further evidence of cell damage a

45 unctions as a cytosine derivate to stimulate adenosine receptors A1 and A2a, which further activate d

46 tent binding across therapeutically relevant adenosine receptors (A1, A2a, and A3) as well as a poten

47 ave shown that bronchoalveolar epithelial A1-adenosine receptors (A1-AdoR) are activated in influenza

48 Adenosine and functional A1 adenosine receptor (A1AR) availability are supposed to m

49 The A1 adenosine receptor (A1AR) is an important G protein-coup

50 R) and AMPARs in the NAc, and explore how A1 adenosine receptor (A1AR) stimulation may reduce dopamin

51 In vivo imaging of the A1 adenosine receptor (A1AR) using (18)F-8-cyclopentyl-3-(3

52 Since central activation of A1 adenosine receptors (A1ARs) plays an important role in t

53 ve that stimulation of apically localized A1 adenosine receptors (A1ARs) triggers a Gi-Gbetagamma-pho

54 Although agonists selective for adenosine receptors A1R, A2aR, and A2bR are ineffective,

55 Here the authors show that adenosine receptor A2A drives pathological angiogenesis

56 (AD) had increased levels of the Gs-coupled adenosine receptor A2A in astrocytes.

57 hrough inhibition of p38 phosphorylation via adenosine receptors A2a-, A2b-, and protein kinase A-dep

58 appa-opioid receptor (KOR) and the human A2A adenosine receptor (A2A AR).

59 of compound 25 as a potent and selective A2A adenosine receptor (A2AAdoR) antagonist with reasonable

60 MR) spectroscopy with the wild-type-like A2A adenosine receptor (A2AAR) in solution provides a compre

61 non-nucleoside partial agonists for the A2A adenosine receptor (A2AAR).

62 Blockade of A2A adenosine receptors (A2AARs) and inhibition of monoamine

63 e remodeling and promotes dermal fibrosis by adenosine receptor (A2AR) activation.

64 Here, we show that engagement of A2A adenosine receptor (A2AR) acts as a checkpoint that limi

65 The A2A adenosine receptor (A2AR) is a G protein-coupled recepto

66 The cAMP-elevating, Gs protein-coupled A2a adenosine receptor (A2aR) is an evolutionarily conserved

67 lar dynamics simulations of thermostabilized adenosine receptor (A2AR) mutants embedded in either a l

68 Mice lacking A2A adenosine receptor (A2AR) or ecto-5'nucleotidase (an enz

69 se that generates adenosine CD73 and the A2A adenosine receptor (A2AR) that mediates adenosine signal

70 The A2A and A2B adenosine receptors (A2AR and A2BR) are implicated in ma

71 A2A adenosine receptors (A2ARs) are endogenous inhibitor of

72 y D2Rs and enhanced by activation of 2A-type adenosine receptors (A2ARs).

73 drug screen revealed that antagonists of the adenosine receptor A2B (ADORA2B) are preferentially toxi

74 In a wide search for adenosine receptor A2b (Adora2b)-elicited cardioadaptive

75 The adenosine receptor A2b is expressed in the vascular endo

76 Specific blockade of the A2B adenosine receptor (A2BAR) inhibited worm elimination an

77 The A2B adenosine receptor (A2BAR) is a Galpha(s)/alpha(q)-prote

78 report that, among these receptors, the A2b adenosine receptor (A2bAR) is highly expressed in adipoc

79 ypoxia-inducible factor 1a (Hif-1a), and A2B adenosine receptor (a2br) were increased by 10-, 4-, and

80 els of acute inflammation, activation of A2B adenosine receptors (A2BR) in extracellular adenosine-ri

81 -methanocarba-5'-N-alkyluronamidoriboside A3 adenosine receptor (A3AR) agonists lacking an exocyclic

82 experimental neuropathic pain through the A3 adenosine receptor (A3AR, now known as ADORA3) signallin

83 Likewise, addition of antagonists for A2A adenosine receptors abolished the formation of DC-Treg c

84 A1 adenosine receptor activation ameliorates ischemic AKI t

85 ry synapses from basolateral amygdala via A1 adenosine receptor activation and enhanced inhibitory sy

86 Using a novel cell-based assay to visualize adenosine receptor activation in real time, we found tha

87 A2b adenosine receptor activation induced CXCL8 via cAMP-pro

88 We propose that adenosine receptor activation suppresses inflammation an

89 fibrotic signal to cardiac fibroblasts by A2 adenosine receptor activation.

90 wild-type levels, suggesting a dependence on adenosine receptor activity.

91 te (ATP) as well as A(1), A2A, A2B, and A(3) adenosine receptor (ADOR) expression.

92 riptionally controlled pathways to pulmonary adenosine receptor (ADOR) signaling during ALI.

93 e hypothesized that signaling events through adenosine receptors (ADORA1, ADORA2A, ADORA2B, or ADORA3

94 s for adenosine receptors implicated the A2B adenosine receptor (Adora2b) in mediating ENT-dependent

95 gical approaches, we determined that the A2B adenosine receptor (ADORA2B) is essential for adenosine-

96 s renal adenosine preferentially induced A2B adenosine receptor (ADORA2B) production and that enhance

97 sine or a specific antagonist to block A(2B) adenosine receptor (ADORA2B) signaling, we successfully

98 we show that many Receptor cells express the adenosine receptor, Adora2b, while Presynaptic (type III

99 mobilization stimulated by the nonselective adenosine receptor agonist 5'-(N-ethylcarboxamido)adenos

100 ily A(2B) receptors because the nonselective adenosine receptor agonist 5'-N-ethylcarboxamidoadenosin

101 es supplemented with adenosine, but not with adenosine receptor agonist 5'-N-ethylcarboxamidoadenosin

102 Administration of the broad-spectrum adenosine receptor agonist 5'-N-ethylcarboxamidoadenosin

103 Treatment of mice with the nonselective adenosine receptor agonist 5'-N-ethylcarboxamidoadensoin

104 The effect of inosine was mimicked by the adenosine receptor agonist NECA and the A2B receptor ago

105 The adenosine receptor agonist NECA inhibited interferon-gam

106 rated that administration of a selective A2A adenosine receptor agonist to CD73-deficient mice result

107 epithelial (HK-2) cells with a selective A1 adenosine receptor agonist, chloro-N(6)-cyclopentyladeno

108 In the present study, we delivered adenosine receptor agonists and antagonists into the lat

109 n unexpected synergistic interaction between adenosine receptor agonists and phosphodiesterase (PDE)

110 g protection, and they implicate inhaled A2B adenosine receptor agonists in ALI treatment.

111 We have used selective adenosine receptor agonists, antagonists, and PDE inhibi

112 ochrome P450 1A2), adenosine metabolism (for adenosine receptor and AMP deaminase), or catecholamine

113 le of enantiospecific recognition at the A2B adenosine receptor and opens new possibilities in ligand

114 ed crystallographic structures for the A(2A) adenosine receptor and the beta(1) and beta(2) adrenergi

115 Adenosine receptors and beta-adrenoceptors are G-protein

116 udies due to its reported lack of effects on adenosine receptors and phosphodiesterases.

117 characterize the physiological link between adenosine receptors and the gap junction coupling in end

118 sion, at this stage of development, although adenosine receptors and the mechanisms of adenosine clea

119 els as a possible physiological link between adenosine receptors and the regulation of gap junction c

120 ightly regulated by Entpd1/Nt5e activity and adenosine receptors; and ADP-adenosine signaling play an

121 HIFI is inhibited by adenosine receptor antagonism and blockade of cyclooxyge

122 ever, in CHU rats, neither the non-selective adenosine receptor antagonist 8-sulphophenyltheopylline

123 e-dimensional features responsible for A(2B) adenosine receptor antagonist activity.

124 tive interaction between chronic exposure to adenosine receptor antagonist caffeine and genetic influ

125 This effect was prevented by a pan-adenosine receptor antagonist CGS15943, but not by A1 or

126 ith the synthesis of an A2-subtype selective adenosine receptor antagonist in only two steps.

127 We also show that treatment with an A1-adenosine receptor antagonist reduces the severity of lu

128 trolled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients H

129 trolled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients H

130 Controlled Randomized Study of the Selective Adenosine Receptor Antagonist Rolofylline for Patients H

131 transport small therapeutic amounts of an A1 adenosine receptor antagonist to the respiratory centers

132 Because caffeine (a nonselective adenosine receptor antagonist) and selective adenosine A

133 The consumption of caffeine (an adenosine receptor antagonist) correlates inversely with

134 ngested psychoactive drug and a nonselective adenosine receptor antagonist, alters CB function and ve

135 ttent intratumor injection of a nonselective adenosine receptor antagonist, aminophylline (AMO; theop

136 Caffeine (5, 10, or 15 mg/kg), a nonspecific adenosine receptor antagonist, dose-dependently and at h

137 in models, oral intake of caffeine, a potent adenosine receptor antagonist, interferes with acupunctu

138 latory effect on migration was blocked by an adenosine receptor antagonist, MRS1754, ARL67156, an ect

139 lfactory learning and memory by acting as an adenosine receptor antagonist.

140 or antagonist, or a selective A(2A) or A(2B) adenosine-receptor antagonist, negated the resistance to

141 tment with a CD73 antagonist, a nonselective adenosine-receptor antagonist, or a selective A(2A) or A

142 Experiments using adenosine receptor antagonists and cells from A(2B)AR(-/

143 Treatment with selective adenosine receptor antagonists indicated a contribution

144 Three novel families of A2B adenosine receptor antagonists were identified in the co

145 while P2Y-selective receptor antagonists or adenosine receptor antagonists were ineffective.

146 e reversed completely by two different A(2A) adenosine receptor antagonists without affecting T cells

147 n attractive scaffold for the preparation of adenosine receptor antagonists, is the low water solubil

148 2-arylethynyl groups were synthesized as A3 adenosine receptor (AR) agonists and screened in vivo (p

149 Studies have shown that adenosine receptor (AR) agonists can be either anti-infl

150 A(1) adenosine receptor (AR) agonists display antiischemic an

151 d (N)-methanocarba adenosine derivatives (A3 adenosine receptor (AR) agonists) to enhance radioligand

152 of caspase 1 was prevented by broad-spectrum adenosine receptor (AR) antagonism with caffeine and by

153 heir pharmacological characterization as A2A adenosine receptor (AR) antagonists by using in vitro an

154 wever, it is not clear whether adenosine and adenosine receptor (AR) antagonists play any roles in th

155 n-7-amines were designed as new human (h) A3 adenosine receptor (AR) antagonists.

156 cetamidopyridines as potent and selective A3 adenosine receptor (AR) antagonists.

157 Here we report that adenosine receptor (AR) signaling modulates BBB permeabi

158 s were tested by pharmacologic antagonism at adenosine receptor (AR) sites in wild-type mice and in m

159 ed the performance of an agonist-bound A(2A) adenosine receptor (AR) structure in retrieval of known

160 enosine and 2-chloroadenosine derivatives at adenosine receptor (AR) subtypes were studied with bindi

161 Although there are four adenosine receptor (AR) subtypes, the A2AAR is both high

162 deling of agonist binding to the human A(2A) adenosine receptor (AR) was assessed and extended in lig

163 1,5-c]pyrimidines as antagonists of the A(3) adenosine receptor (AR) was explored with the principal

164 Here, we show that activation of the A2A adenosine receptor (AR) with an FDA-approved A2A AR agon

165 with the main purpose of targeting the hA2A adenosine receptor (AR).

166 Stimulation of A2A adenosine receptors (AR) promotes anti-inflammatory resp

167 to G protein-coupled receptors including the adenosine receptors (AR), which are involved in a pletho

168 Because all adenosine receptors are expressed on osteoclasts, we det

169 Adenosine receptor (ARs) and P2Y receptors (P2YRs) that

170 stituted-1,2,4-triazolo[1,5-c]pyrimidines as adenosine receptors (ARs) antagonists has been explored.

171 Because A2B adenosine receptors (ARs) are important regulators of ma

172 Adenosine derivatives developed to activate adenosine receptors (ARs) revealed micromolar activity a

173 nts against homology models of the A3 and A1 adenosine receptors (ARs) with the goal to discover A3AR

174 oside and a ligand of four G protein-coupled adenosine receptors (ARs), which are the A(1)AR, A(2A)AR

175 affinity at both mouse (m) and human (h) A3 adenosine receptors (ARs), while a N(6)-p-sulfophenyleth

176 ntified as structurally novel antagonists at adenosine receptors (ARs).

177 -coupled receptors, the A1, A2A, A2B, and A3 adenosine receptors (ARs).

178 used a folding-defective mutant of human A1-adenosine receptor as a sensor to explore whether endoge

179 These studies identify ENT1 and adenosine receptors as key to the process of reestablish

180 Adenosine then acts on A1 adenosine receptors at neighboring excitatory Schaffer c

181 w series of allosteric modulators for the A1 adenosine receptor based on the 2-amino-3-(p-chlorobenzo

182 l chemotypes may be discovered for the A(2A) adenosine receptor, based on complementarity to its rece

183 wever, systemic adverse effects may limit A1 adenosine receptor-based therapy for ischemic AKI, indic

184 romodulator in the mammalian retina, with A1 adenosine receptors being especially prevalent in the in

185 t observed in those animals administered the adenosine receptor blocker 8-(p-sulfophenyl)theophylline

186 on that is usually treated with caffeine, an adenosine receptor blocker that has powerful influences

187 pressive A2ARs that are potential targets of adenosine receptor blockers to enhance immune killing of

188 crosecond-timescale simulations of the A(2A) adenosine receptor bound to either of two agonists, aden

189 The crystal structure of the human A(2A) adenosine receptor bound to the A(2A) receptor-specific

190 Most studies focus on effects of caffeine on adenosine receptors, but there is evidence for other, mo

191 We reengineered the human A(2A) adenosine receptor by replacing its third intracellular

192 mouse lung and that activation of A1-subtype adenosine receptors by adenosine contributes significant

193 A2A adenosine receptors control pancreatic dysfunction in hi

194 tic potentiation in oriens, whereas NMDA and adenosine receptors counteracted unpaired stratum oriens

195 Activation of A2A adenosine receptors decreases inflammation and gastritis

196 Next, using 4 adenosine receptor-deficient mice and pharmacological ap

197 ld type, ecto-5'-nucleotidase-deficient, and adenosine receptor-deficient mice undergo 5'-AMP-induced

198 ceptor-deficient or renal proximal tubule A1 adenosine receptor-deficient mice.

199 perimental therapeutics targeting individual adenosine receptors demonstrate strong prophylactic or t

200 at integrates gap junction coupling into the adenosine receptor-dependent signalling of endothelial c

201 nflammatory actions that were coupled to A2a adenosine receptor-dependent upregulation of tribbles ho

202 lates neovascularization in part through A2B adenosine receptor-dependent upregulation of vascular en

203 is lung carcinoma (LLC) cells, we found that adenosine receptor-dependent upregulation of VEGF produc

204 However, the therapeutic potential of adenosine receptor-directed ligands for neuroprotection

205 Knockdown of A2b adenosine receptor disrupted scl(+) hemogenic vascular e

206 or), opioid receptors, adrenergic receptors, adenosine receptors, dopamine receptor, and sphingosine

207 '-methyluronamides containing known A(3) AR (adenosine receptor)-enhancing modifications, i.e., 2-(ar

208 st (ABA-X-BY630) from the human A(1) or A(3) adenosine receptors expressed in CHO-K1 cells has provid

209 antitumor immunity through the activation of adenosine receptors expressed on multiple immune subsets

210 Allosteric binding sites on the adenosine receptor family represent potential therapeuti

211 Targeting retinal A1 adenosine receptors for ipRGC inhibition represents a po

212 The four subtypes of adenosine receptors form relevant drug targets in the tr

213 lective regulatory mechanism for fine-tuning adenosine receptor function in the nervous system.

214 Furthermore, mice lacking adenosine receptors had no defect in cyst formation.

215 Engineering the human A2A adenosine receptor has allowed structures to be solved i

216 Adenosine 5'-triphosphate and adenosine receptors have been identified in adult and fe

217 Agonists that target the A1, A2A, A2B and A3 adenosine receptors have potential to be potent treatmen

218 Furthermore, studies in genetic models for adenosine receptors implicated the A2B adenosine recepto

219 enosine and signaling events through the A2B adenosine receptor in lung protection.

220 Finally, genetic studies implicated the A2B adenosine receptor in netrin-1-mediated protection durin

221 aria treatment resulting from binding to the adenosine receptor in the human brain.

222 gonist activation slows diffusion of the A2A adenosine receptor in the lipid bilayer.

223 nd its loss were investigated: expression of adenosine receptors in CB (A(2B)) was down-regulated and

224 e for adenosine generation and engagement of adenosine receptors in conferring in vivo resistance to

225 Moreover, we evaluated the potential role of adenosine receptors in DF-EC interaction and if DF effec

226 not show any evidence of the involvement of adenosine receptors in DF-EC interaction.

227 In conclusion, the stimulation of adenosine receptors in hCMEC/D3 cells induces a Ca(2+) i

228 Altered levels of adenosine receptors in periodontal disease also suggest

229 In this study, we studied the role of A(2B) adenosine receptors in regulating the mortality and infl

230 ine receptors (A(2B)ARs) are the predominant adenosine receptors in the intestinal epithelium.

231 esults suggest novel approaches to targeting adenosine receptors in the promotion of bone regeneratio

232 monstrate that adenosine, bound to A1 and A3 adenosine receptors, increases cytokine secretion by LPS

233 cAMP and VASP-P in the absence of ADP in an adenosine receptor-independent manner.

234 d that tissue-specific expression of the A2B adenosine receptor is responsible for the previously des

235 Comprehensive examination of adenosine receptor-knockout mice exposed to AKI demonstr

236 uation of emerging Rho-kinase inhibitors and adenosine receptor ligands that offer the potential to i

237 compounds purchased, six novel high affinity adenosine receptor ligands were confirmed experimentally

238 generation of adenosine or activation of A1-adenosine receptors may be beneficial in treating influe

239 These results indicate that adenosine receptors may be useful targets for the treatm

240 n against OIR, effective therapeutic window, adenosine receptor mechanisms, and neuroglial involvemen

241 While previous studies have focused on adenosine-receptor mediated mechanisms for caffeine acti

242 cally approved hematopoietic cytokine, in A1 adenosine receptor-mediated induction of sphingosine kin

243 Adenosine receptor-mediated regulation of monocyte/macro

244 ubule IL-11 is a critical intermediary in A1 adenosine receptor-mediated renal protection that warran

245 Adenosine/adenosine receptor-mediated signaling has been implicate

246 The effects were A1 adenosine receptor-mediated, and the expression of this

247 We found that A(2B) adenosine receptors on hematopoietic cells play an impor

248 Because stimulation of A2B adenosine receptors on mouse cardiac stem cell antigen (

249 ontribute to disease pathology by activating adenosine receptors on red blood cells.

250 dition to previously noted direct effects of adenosine receptors on regulatory T cell development and

251 reated with CGS 21680, an agonist of the A2A adenosine receptor or NF449, a P2X1 antagonist.

252 TP degradation; (2) inhibited P2Y receptors, adenosine receptors, or KATP channels; or (3) inhibited

253 elor and clopidogrel had no direct impact on adenosine receptors (p = not significant).

254 es ATP and AMP, and signaling events through adenosine receptors, play a critical role in attenuating

255 Because each of these adenosine receptors plays a distinct role throughout the

256 e A(3)AR in HEK293T cells containing a mixed adenosine receptor population.

257 of BRAF and MEK in combination with the A2A adenosine receptor provided significant protection again

258 f adenosine are increased during sepsis, and adenosine receptors regulate the host's response to seps

259 An increase in adenosine receptor responsiveness to endogenous adenosin

260 Blocking breast cancer cell A3 adenosine receptors resulted in higher extravasation rat

261 Blockade of adenosine receptors selectively increased IPSCs evoked f

262 Transcript levels of renal adenosine receptors showed a selective induction of Ador

263 indings suggest that alveolar epithelial A2B adenosine receptor signaling contributes to lung protect

264 ed by enhancing or blocking CD73 activity or adenosine receptor signaling depending on the clinical i

265 otidase-dependent adenosine production or A1-adenosine receptor signaling in the auditory thalamus.

266 along the adenine nucleotide metabolism and adenosine receptor signaling pathways.

267 protective effect of exogenous cAMP required adenosine receptor signaling.

268 generation of adenosine, but independent of adenosine receptor signaling.

269 th by limiting antitumor T-cell immunity via adenosine receptor signaling.

270 The A(2A) adenosine receptor signals in the periphery and the CNS,

271 To directly deliver an A2B adenosine receptor-specific agonist to alveolar epitheli

272 The response to adenosine receptor stimulation was impaired in eKO mice

273 ation of EF2K occurs in response to A2A-type adenosine receptor stimulation, and that activation of p

274 We show that, after TLR/adenosine receptor stimulation, NR4A2 depletion promotes

275 39) is absolutely conserved across the human adenosine receptor subfamily.

276 Adenosine receptor subtype (A(1), A(2A), A(2B), and A(3)

277 Stimulation of the adenosine receptor subtype A2B increases the gap junctio

278 ed to evaluate the impact of the A2A and A2B adenosine receptor subtype agonist 2-phenylaminoadenosin

279 Expressed adenosine receptor subtypes and connexin (Cx) isoforms w

280 Indeed, activation of the adenosine receptor subtypes expressed by a broad range o

281 h a comparison of the sequences of different adenosine receptor subtypes from different species, we p

282 lthough the nature of the immune subsets and adenosine receptor subtypes involved in this process are

283 Several adenosine receptor subtypes on endothelial, epithelial,

284 de adenosine (NECA) (10 muM; agonist for all adenosine receptor subtypes) and CGS21680 (10 muM; selec

285 tion, but contrasting signaling profiles, of adenosine receptor subtypes, these compounds might have

286 ation, particularly in the presence of other adenosine receptor subtypes.

287 0.12) and is >650-fold selective over other adenosine receptor subtypes.

288 rt of the binding cavity is conserved across adenosine receptor subtypes.

289 g that Adora3i2 specifies a functional A3Ri2 adenosine receptor that couples through Galpha(i).

290 s can be translated into a clinical setting, adenosine receptor therapeutics may become an integral p

291 re of gene-targeted mice for each individual adenosine receptor to liver ischemia and reperfusion rev

292 Molecular dynamics simulations of the A(2A) adenosine receptor totaling 1.4 mus show clear evidence

293 The A(2A)-adenosine receptor undergoes restricted collision coupli

294 selectivity of ZM241385 for the human A(2A) adenosine receptor, we examined the effect of mutating a

295 The interactions of hypoxia-->adenosine-->adenosine receptors were tested by pharmacologic antagon

296 ently inhibited by activation of presynaptic adenosine receptors, whereas IPSCs evoked from RMTg were

297 P formation and hypertrophy by activating A1 adenosine receptors while delivering an antifibrotic sig

298 Moreover, blockade of the A2A adenosine receptor with a selective antagonist also augm

299 oMFA) method, on 52 antagonists of the A(2B) adenosine receptor with known biological activity were p

300 These effects were mimicked by antagonism of adenosine receptors with 8-(p-sulfophenyl) theophylline.